Synthesis of 4-methoxybenzoylhydrazones and evaluation of their antiglycation activity

Article abstract of DOI:10.3390/molecules19011286

A series of 4-methoxybenzoylhydrazones 1-30 was synthesized and the structures of the synthetic derivatives elucidated by spectroscopic methods. The compounds showed a varying degree of antiglycation activity, with IC50 values ranging between 216.52 and 748.71 M, when compared to a rutin standard (IC50 = 294.46 1.50 M). Compounds 1 (IC50 = 216.52 4.2 M), 3 (IC50 = 289.58 2.64 M), 6 (IC50 = 227.75 0.53 M), 7 (IC50 = 242.53 6.1) and 11 (IC50 = 287.79 1.59) all showed more activity that the standard, and these compounds have the potential to serve as possible leads for drugs to inhibit protein glycation in diabetic patients. A preliminary SAR study was performed.

Full text of DOI:10.3390/molecules19011286

Molecules 2014, 19, 1286-1301; doi:10.3390/molecules19011286
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis of 4-Methoxybenzoylhydrazones and Evaluation of
Their Antiglycation Activity
Muhammad Taha 1,2,*, Humera Naz 1,3, Saima Rasheed 4, Nor Hadiani Ismail 1,2
,
Aqilah Abd Rahman 1,3, Sammer Yousuf 4 and Muhammad Iqbal Choudhary 1,4
1
Atta-ur-Rahman Institute for Natural Product Discovery, Universiti Teknologi MARA,
Puncak Alam Campus, Shah Alam 42300, Malaysia
2
Faculty of Applied Sciences, Universiti Teknologi MARA, Shah Alam 40450, Malaysia
3
Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Shah Alam 42300, Malaysia
4
H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences,
University of Karachi, Karachi 75270, Pakistan
* Author to whom correspondence should be addressed; E-Mail: taha_hej@yahoo.com or
muhamm9000@puncakalam.uitm.edu.my; Tel.: +60-33-258-4761; Fax: +60-33-258-4770.
Received: 17 December 2013; in revised form: 31 December 2013 / Accepted: 2 January 2014 /
Published: 21 January 2014
Abstract: A series of 4-methoxybenzoylhydrazones 1–30 was synthesized and the
structures of the synthetic derivatives elucidated by spectroscopic methods. The compounds
showed a varying degree of antiglycation activity, with IC50 values ranging between 216.52
and 748.71 µM, when compared to a rutin standard (IC50 = 294.46 ± 1.50 µM). Compounds 1
(IC50 = 216.52 ± 4.2 µM), 3 (IC50 = 289.58 ± 2.64 µM), 6 (IC50 = 227.75 ± 0.53 µM), 7
(IC50 = 242.53 ± 6.1) and 11 (IC50 = 287.79 ± 1.59) all showed more activity that the
standard, and these compounds have the potential to serve as possible leads for drugs to
inhibit protein glycation in diabetic patients. A preliminary SAR study was performed.
Keywords: 4-methoxybenzoylhydrazones; antiglycation activity; rutin; AGEs;
protein glycation inhibition; diabetes
1. Introduction
Benzoylhydrazones have many applications in medicinal and analytical chemistry [1–3].
Benzoylhydrazones of different heterocyclic compounds were reported to possess antiproliferative [4],

Molecules 2014, 19
1287
anticonvulsant [5], antioxidant [6], cytotoxicity and anti-HIV activities [7,8]. Numerous benzoylhydrazones
have shown interesting bioactivities, such as antibacterial, antifungal, antiinflammatory, antimalarial,
analgesic, antiplatelet, anticancer, antituberculosis [9–17], insecticidal, antiplasmodium, and
antimycobacterial effects, as adriamycin immunoconjugates, proteinase inhibitors and activity against the
parasite Trypanosoma brucei [18–22]. Their hydrazide derivatives have shown β-glucuronidase
inhibition activity [23]. In addition, substituted acylhydrazide Schiff bases are reported to have a wide
range of bioactivities, including anticancer [24], antitubercular, and anti-inflammatory activities [25].
Hydrazine derivatives also have several commercial applications [26].
Glycation is a non-enzymatic chemical process in which biomolecules (such as proteins, human
DNA, and lipids) are damaged by the attachment of reducing sugars (e.g., glucose), finally leading to
the formation of highly reactive so-called advanced glycation end products (AGEs). This process has
been associated with deleterious health effects. Protein glycation has been implicated in the
development of pathologies associated with diabetes and ageing etc. [27]. Therefore, the discovery of
anti-glycation agents is among the most promising approaches for the management of late diabetic
complications. At present only a few glycation inhibitors are known and the requirement of novel
glycation inhibitors is still unmet [28]. With the epidemic-like spread of type-2 diabetes, the onsets of
late diabetic complications, such as cardiopathy, retinopathy, neuropathy, nephropathy, are on rise.
This is largely due to the formation of advanced glycation end products (AGEs) [29,30]. Major efforts
have recently been focused on the discovery of new, safe and effective glycation inhibitors [31].
Few molecules are reported to cleave cross-links formed by AGEs, and possibly provide the exciting
opportunity of reversing the process of late diabetic complications [32]. It has been discovered that
aged garlic extract possess excellent antiglycation potential in vitro [33,34]. Aminoguanidine was
found to inhibit AGE formation and prevent retinopathy and diabetic vascular complications in diabetic
animals, but it showed toxicity problems in phase III clinical trials [35]. Some other molecules
(e.g., spermine, spermidine and polyamines) were also reported to have potent anti-glycation potential,
similar to those of aminoguanidine and carnosine, but these compounds have to be addressed in future
in vivo studies [36]. In the search of new, effective and safe antiglycation agents, we have reported several
classes of compounds from natural flora, such as cyclopeptide alkaloids from Ziziphus oxyphylla Edgw,
polyphenolic compounds from Parmotrema cooperi, kaempferol-7-β-D-glucopyranoside from
Carum petroselinum, flavanones and flavones from Iris tenuifolia and Otostegia persica (Burm.) Boiss,
respectively [37–40]. Along with natural compounds we have also reported different classes of
synthetic compounds having antiglycation properties in the recent past, such as acylhydrazide [41],
benzophenonehydrazone [42], 2,4,6-trichlorophenylhydrazones [43], oxindole derivatives [44], bis-Schiff
bases of isatin [45] and metronidazole esters [46]. The work reported here is in continuation of this
same systematic study.
2. Results and Discussion
2.1. Chemistry
4-Methoxybenzoylhydrazones 1–30 were synthesized from 4-methoxybenzoylhydrazide, which
were obtained from methyl 4-methoxybenzoate by refluxing with hydrazine hydrate for 2 h.

Molecules 2014, 19
1288
The 4-methoxybenzoylhydrazide obtained was recrystallized from methanol. 4-Methoxy- benzoylhydrazones
1–30 were prepared by refluxing 4-methoxybenzoylhydrazide with different aldehydes in methanol for
3 to 4 h (Scheme 1). The crude products were further recrystallized from methanol and mostly needle-
like crystals were obtained in 78%–92% yield. The structures of the 4-methoxybenzoylhydrazones
were deduced using various spectroscopic techniques and CHN analyses. The configuration of C=N
double bond is E, which can be seen by various crystal structures of similar structures we have
published [47–56].
Scheme 1. Synthesis of 4-Methoxybenzoylhydrazones 1–30.
O
O
O
R
O
NH2
N2H4H2O
Methanol
Reflux 6 h.
R
N
Methanol
H
OMe
N
H
N
H
Reflux 3 h.
MeO
MeO
MeO
Entry
1
Structure
Yield (%) Entry
Structure
Yield (%)
1
1
HO
OH
6
2
82
78
84
85
16
17
18
19
85
87
88
90
3
5
N
5
4
OH
1
4
O
2
6
1
2
3
4
3
HO
OH
2
OH
OCH3
1
1
OH
OH
OCH3
6
5
O
3
5
4
OCH3
1
1
6
2
OH
6
5
OCH3
3
HO
4
OCH3
1
1
6
5
6
2
2
5
6
86
81
20
21
92
90
3
OH
5
OH
1
4
1
6
2
OH
6
5
3
5
3
O
OH
H3CO
1
1
6
2
2
6
7
83
22
82
3
5
HO
OH
4
F
1
1
6
2
6
2
8
9
88
90
23
24
90
92
3
5
5
OCH3
4
OH
1
1
6
2
3
OH
6
5
5
3
4
OCH3

Molecules 2014, 19
1289
Scheme 1. Cont.
Entry
10
Structure
Yield (%) Entry
Structure
Yield (%)
1
1
6
2
6
2
87
92
90
87
25
26
27
28
91
3
5
5
OH
4
1
Cl
6
2
3
s
11
12
13
88
88
87
5
OCH3
4
5
OH
1
1
6
6
2
2
5
5
OH
Br
OCH3
OH
1
1
6
I
OH
6
5
3
OH
H3CO
4
OCH3
1
1
6
5
2
6
5
N
14
15
80
82
29
30
3
84
90
3
NO2
4
1
1
2
6
6
5
2
3
H3CO
OCH3
N
4
2.2. Antiglycation Activity
Structure Activity Relationship
The NH2 groups of aminoguanidine and other nitrogen-containing compounds are well known to form
Schiff base adducts with the carbonyl moieties of sugars. This interaction is mainly responsible for
inhibiting the formation of advanced glycation end product (AGEs). Additionally, it has been found that
compounds with different substituents have varying degree of activity against protein glycation [47–56].
Based on this, we have prepared a series of 4-methoxybenzoylhydrazones 1–30 and evaluated their
antiglycation potential in vitro. For our anti-glycation studies two standards, namely aminoguanidine
and rutin, were used. In our protein model system (BSA-MG glycation model), aminoguanidine
showed an IC50 value of 1168.24 ± 1.2 µM, while rutin showed an IC50 value of 294.5 ± 1.5 µM.
However, as rutin is more active against glycation than aminoguanidine, we therefore decided to use
rutin as the standard in this assay. The compounds 1–30 showed potent to moderate antiglycation
activities, with IC50 values ranging between 216.52 and 748.71 µM, when compared to the standard
compound. Compounds 1, 3, 6, 7, and 11 (IC50 = 216.52 ± 4.2 µM, 289.58 ± 2.64 µM, 227.75 ± 0.53 µM,
242.53 ± 6.1 µM and IC50 = 287.79 ± 1.59 µM, respectively), showed more potent activities than the
rutin standard. The compounds 4 (IC50 = 307.1 ± 6.08 µM), 8 (IC50 = 347.62 ± 5.8 µM),
2 (IC50 = 394.76 ± 3.35 µM) and 12 (IC50 = 399.90 ± 7.9 µM) showed good activity. Compounds 5
(IC50 = 420.40 ± 3.3 µM) and 17 (IC50 = 474.97 ± 19.14 µM) showed moderate activities. Compounds

Molecules 2014, 19
1290
14 (IC50 = 649.18 ± 18.5 µM), 10 (IC50 = 657.75 ± 14.0 µM), 18 (IC50 = 718.96 ± 10.7 µM) and
15 (IC50 = 748.71 ± 7.8 µM) were only weakly active (Table 1).
Table 1. In vitro protein glycation inhibitory activity of compounds 1–30.
Compounds
IC50 (µM ± SEM a)
216.52 ± 4.2
394.76 ± 3.35
289.58 ± 2.64
307.1 ± 6.08
420.40 ± 3.3
227.75 ± 0.53
242.53 ± 6.1
347.62 ± 5.8
NA b
Compounds
IC50 (µM ± SEM a)
NA b
1
2
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
474.97 ± 19.14
718.96 ± 10.7
NA b
3
4
5
NA b
6
NA b
7
NA b
8
NA b
9
NA b
10
11
12
13
14
15
657.75 ± 14.0
287.79 ± 1.59
399.90 ± 7.9
NA b
NA b
NA b
NA b
NA b
649.18 ± 18.5
748.71 ± 7.8
NA b
NA b
Standard Rutin c
294.5 ± 1.50
a SEM is the standard error of the mean. b NA Not active. c Rutin: standard inhibitor for antiglycation activity.
The preliminary structure activity relationship data suggests that the activity mainly depends on the
number, as well as the position of hydroxyl substituent’s on the phenyl moiety. Compounds 1 and 2 are
both trihydroxy substituted, but compound 1 showed better activity (IC50 = 216.52 ± 4.2 µM) than the
standard rutin. The activity of these compounds might be due to their capacity to inhibit glycoxidation.
Compound 2 showed very low activity (IC50 = 394.76 ± 3.35 µM), as compared to compound 1.
This may be due to the intra-molecular hydrogen bonding in compound 2, which reduce its chances to
inhibit glycoxidation as compared to compound 1 (Figure 1).
Figure 1. Comparison of the anti-glycation activity of compounds 1 and 2.
The five compounds having dihydroxy substituents (i.e., 6, 7, 3, 4 and 5) showed excellent to moderate
activity, depending upon the position of the hydroxyl groups. Compounds 6 (IC50 = 227.75 ± 0.53 µM),
7 (IC50 = 242.53 ± 6.1 µM) and 3 (IC50 = 289.58 ± 2.64 µM) showed more potent activity than the
standard (rutin), whereas compounds 4 (IC50 = 307.1 ± 6.08 µM) showed activity comparable to the
standard. Compound 5 showed moderate activity (Table 1). As discussed earlier, the antiglycation
activity mainly depends on the position and potential of hydroxy groups to inhibit glycoxidation.

Molecules 2014, 19
1291
In compounds 6, the 2,4-dihydroxy groups, being far apart from each other, have no hydrogen bonding
with each other. para-Hydroxy groups easily inhibit glycoxidation and hence a potent anti-glycation
activity was observed. In compound 7, both hydroxys are at the meta position and it showed potent
anti-glycation activity, with an IC50 value of 242.53 ± 6.1 µM. In compounds 3 and 4, the meta-hydroxy
moieties are still free to inhibit glycoxidation, but the activity was decreased with IC50 values of
289.58 ± 2.64 and 307.1 ± 6.08 µM, respectively. In compound 5, the ortho-hydroxyl groups are
involved in intramolecular hydrogen bonding therefore a weak activity was observed as compared to
its analogs, i.e., compounds 6, 7, 3 and 4 (Table 1).
The monohydroxyl-substituted analogues showed varied activities, mainly depending on the
position of the hydroxyl group. Compound 8 (IC50 = 347.62 ± 5.8 µM) is the most active analogue
among the monohydroxy derivatives, with a hydroxyl group at the para position. When the hydroxy group
is at the meta position, the activity is reduced by half as compared to compound 8, (compound 10;
IC50 = 657.75 ± 14.0 µM). Interestingly when the hydroxy is at the ortho position, as in compound 9,
the activity was completely lost.
Compounds 11–13 having one hydroxy and one methoxy group showed varied activity, depending
upon the position of the hydroxyl substituent. Compound 11 (IC50 = 287.79 ± 1.59 µM) having a
para-hydroxy, showed better activity than the standard, whereas its analogue 12 (IC50 = 399.90 ± 7.9 µM)
with a meta hydroxy showed a moderate activity against protein glycation. Compound 13 with an
ortho hydroxy was found to be inactive.
Compounds 14–16 possess diverse pyridine rings. The most active among the pyridine derivatives
was compound 14 (IC50 = 649.18 ± 18.5 µM), with the nitrogen at position-3, near to the hydrazine
bridge. The activity decreases sharply when the nitrogen shifts to position-4, as in case of compound
15 (748.71 ± 7.8 µM). Compound 16 with the nitrogen at position-2was found to be completely
inactive (Table 1).
Compounds 17 and 18 showed a weak activity. Compound 17 possess a furfuryl ring and its low
activity may be due to the weak interaction of the ring oxygen to inhibit glycoxidation. Furthermore,
compound 18 possess an ester moiety, which again interacts weakly with the amino group of the
proteins and hence showed a weak activity. Additionally compounds 9, 13 and 18–30 were also found
to be inactive.
In conclusion, compounds having hydroxy groups at suitable positions, especially at the para position,
can inhibit glycoxidation, and thus exhibit a potent antiglycation activity. However, structural
modifications can be optimized to achieve the desired activity in this class of compounds.
3. Experimental
3.1. General Information
NMR experiments were performed on a Bruker Ultra Shield FT NMR 500 MHz (Wissembourg,
Switzerland). CHN analysis was performed on a Carlo Erba Strumentazione-Mod-1106 (Milan, Italy).
Electron impact mass spectra (EI-MS) were recorded on a Finnigan MAT-311A instrument (Bremen,
Germany). Thin layer chromatography (TLC) was performed on pre-coated silica gel aluminum plates

Molecules 2014, 19
1292
(Kieselgel 60, 254, E. Merck, Darmstadt, Germany). Chromatograms were visualized by UV at 254
and 365 nm.
3.2. Experimental Protocol
3.2.1. Synthesis of 4-Methoxybenzohydrazide
Methyl 4-methoxybenzoate (10g) was refluxed with the mixture of hydrazine hydrate (10 mL) and
methanol (25 mL) for 6 h. The excess hydrazine and methanol were evaporated to give the crude
product which was recrystallized from methanol to yield 92% pure 4-methoxybenzohydrazide.
3.2.2. General Procedure for the Synthesis of 4-Methoxybenzohydrazone Derivatives
The 4-methoxybenzohydrazide derivatives were synthesized by refluxing in methanol a mixture of
2 mmol each of 4-methoxybenzohydrazide with different aldehydes and a catalytic amount of acetic
acid for 3 h. After the completion of the reaction, the solvent was evaporated under vacuum to afford
the crude products which were further recrystallized from methanol to afford needle-like pure products
in most of the cases in good to excellent yields.
1
N'-(2,4,6-Trihydroxybenzylidiene)-4-methoxybenzohydrazide (1). Solid, M.p.: >250 °C; H-NMR
(DMSO-d6):  11.77 (s, 1H, NH), 11.12 (s, 2H, OH), 9.81 (s, 1H, OH), 8.80 (s, 1H, N=CH-Ar),
7.93 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.07 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 5.85 (s, 2H, H-3, H-5),
3.83 (s, 3H, OCH3); Anal. Calcd for C15H14N2O5: C = 59.60, H = 4.67, N = 9.27, O = 26.46, Found
C = 59.58, H = 4.65, N = 9.24, O = 26.44; EI MS m/z (% rel. abund.): 302. (M+, 10), 284 (45),
167 (25), 135 (100).
1
N'-(3,4,5-Trihydroxybenzylidiene)-4-methoxybenzohydrazide (2). Solid, M.p.: >250 °C; H-NMR
(DMSO-d6):  11.46 (s, 1H, NH), 11.32 (s, 2H, OH), 9.61 (s, 1H, OH), 8.16 (s, 1H, N=CH-Ar),
7.89 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.07 (d, 2H, J3,5/ 2,6 = 9.0 Hz, H-3, H-5), 6.70 (s, 2H, H-2, H-6),
3.83 (s, 3H, OCH3); Anal. Calcd for C15H14N2O5: C = 59.60, H = 4.67, N = 9.27, O = 26.46, Found
C = 59.57, H = 4.64, N = 9.25, O = 26.43; EI MS m/z (% rel. abund.): 302 (M+, 5), 284 (25), 139 (20),
135 (100).
1
N'-(2,3-Dihydroxybenzylidene)-4-methoxybenzohydrazide (3). Solid, M.p.: 231°C; H-NMR (DMSO-d6):
 12.01 (s, 1H, NH), 11.26 (s, 1H, OH), 9.61 (s, 1H, OH), 8.58 (s, 1H, N=CH-Ar), 7.95 (d, 2H,
J2,6/3,5 = 9.0 Hz, H-2 , H-6), 7.10 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.96 (dd, 1H, J4,5 = 6.5,
J4,6 = 2.0 Hz, H-4), 6.86 (dd, 1H, J6,5 = 6.5, J6,4 = 2.0 Hz, H-6), 6.76 (t, 1H, J5(4,6) = 6.5 Hz, H-5),
3.85 (s, 3H, OCH3); Anal. Calcd for C15H14N2O4: C = 62.93, H = 4.93, N = 9.79, O = 22.35, Found
C = 62.91, H = 4.90, N = 9.77, O = 22.32; EI MS m/z (% rel. abund.): 286 (M+, 12), 268 (20),
135 (100), 109 (15).
1
N'-(2,5-Dihydroxybenzylidene)-4-methoxybenzohydrazide (4). Solid, M.p.: 237 °C; H-NMR (DMSO-d6):
 12.01 (s, 1H, NH), 11.27 (s, 1H, OH), 9.22 (s, 1H, OH), 8.57 (s, 1H, N=CH-Ar),
7.95 (d, 2H, J2,6/ 3,5 = 9.0 Hz, H-2 , H-6), 7.09 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.96 (dd, 1H, J4,3 = 8.0,

Molecules 2014, 19
1293
J4,6 = 2.0 Hz, H-3), 6.86 (d, 1H, J6,4 = 2.0 Hz, H-6), 6.75 (d, 1H, J3,4 = 8.0 Hz, H-3), 3.85 (s, 3H, OCH3);
Anal. Calcd for C15H14N2O4: C = 62.93, H = 4.93, N = 9.79, O = 22.35, Found C = 62.91, H = 4.90,
N = 9.77, O = 22.31; EI MS m/z (% rel. abund.): 286 (M+, 6), 268 (18), 135 (100), 109 (18).
1
N'-(3,4-Dihydroxybenzylidene)-4-methoxybenzohydrazide (5). Solid, M.p.: 239 °C; H-NMR (DMSO-d6):
 11.47 (s, 1H, NH), 9.41 (s, 2H, OH),  8.25 (s, 1H, N=CH-Ar), 7.90 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6),
(s, 1H, H-6), 7.06 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.93 (d, 1H, J3,2 = 8.0 Hz, H-4),
6.79 (d, 1H, J2,3 = 8.0 Hz, H-2), 3.84 (s, 3H, OCH3); Anal. Calcd for C15H14N2O4, C = 62.93, H = 4.93,
N= 9.79, O = 22.35, Found C = 62.91, H = 4.90, N = 9.77, O = 22.32; EI MS m/z (% rel. abund.):
286 (M+, 17), 268 (22), 135 (100), 109 (9).
N'-(2,4-Dihydroxybenzylidene)-4-methoxybenzohydrazide (6). Solid, M.p.: >250 °C; 1H-NMR
(DMSO-d6):  11.85 (s, 1H, OH) 11.56 (s, 1H, OH), 9.98 (s, 1H, OH), 8.41 (s, 1H, N=CH-Ar),
7.92 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.30(d, 1H, J6,5 = 8.5 Hz, H-6), 7.08 (d, 2H, J3,5/2,6 = 9.0 Hz,
H-3, H-5), 6.37 (dd, 1H, J5,6 = 8.5, J5,3 = 2.0 Hz, H-5), 6.32 (d, 1H, J3,5 = 2.0 Hz, H-3), 3.89 (s, 3H, OCH3);
Anal. Calcd for C15H14N2O4: C = 62.93, H = 4.93, N = 9.79, O = 22.35, Found C = 62.91, H = 4.90,
N = 9.77, O = 22.31; EI MS m/z (% rel. abund.): 286 (M+, 11), 268 (13), 135 (100), 109 (25).
N'-(3,5-Dihydroxybenzylidene)-4-methoxybenzohydrazide (7). Solid, M.p.: >250 °C; 1H-NMR
(DMSO-d6):  11.60 (s, 1H, OH) 9.49 (s, 2H, OH), 8.23 (s, 1H, N=CH-Ar), 7.92 (d, 2H, J2,6/3,5 = 9.0 Hz,
H-2, H-6), 7.06 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.60 (s, 2H, H-2,H-6), 6.26 (t, 1H, J4(2,6) = 2.0 Hz,
H-4), 3.83 (s, 3H, OCH3); Anal. Calcd for Anal. Calcd for C15H14N2O4: C = 62.93, H = 4.93,
N= 9.79, O = 22.35, Found C = 62.91, H = 4.90, N = 9.77, O = 22.31; EI MS m/z (% rel. abund.):
286 (M+, 6), 268 (17), 135 (100), 109 (22).
N'-(4-Hydroxybenzylidene)-4-methoxybenzohydrazide (8). Solid, M.p.: >250 °C; 1H-NMR (DMSO-d6):
 11.54 (s, 1H, NH), 9.93 (s, 1H, OH), 8.32 (s, 1H, N=CH-Ar), 7.90 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6),
7.57 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2/H-6), 7.06 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5) 6.84 (d, 2H J3,5/2,6 = 8.5 Hz,
H-3/H-5), 3.83 (s, 3H, OCH3); Anal. Calcd for C15H14N2O3: C = 66.66, H = 5.22, N= 10.36, O = 17.76,
Found C = 66.64, H = 5.20, N = 10.33, O = 17.73; EI MS m/z (% rel. abund.): 270 (M+, 30), 268 (15),
135 (100), 93 (45).
1
N'-(2-Hydroxybenzylidiene)-4-methoxybenzohydrazide (9). Solid, M.p.: 183 °C; H-NMR (DMSO-d6):
 12.02 (s, 1H, NH), 11.40 (s, 1H, OH), 8.62 (s, 1H, N=CH-Ar), 7.95 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6),
7.53 (d, 1H, J3,4 = 7.5, H-3), 7.32 (t, 1H, J5(4,6) = 8.5 Hz, H-5), 7.09 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5),
6.95–6.90 (m, 2H, H-4/H-6), 3.84 (s, 3H, OCH3); Anal. Calcd for C15H14N2O3: C = 66.66, H = 5.22,
N= 10.36, O = 17.76, Found C = 66.63, H = 5.19, N = 10.32, O = 17.74; EI MS m/z (% rel. abund.):
270 (M+, 70), 268 (14), 135 (100), 93 (15).
1
N'-(3-Hydroxybenzylidene)-4-methoxybenzohydrazide (10). Solid, M.p.: 219 °C; H-NMR (DMSO-d6):
 11.63 (s, 1H, NH), 9.66 (s, 1H, OH), 8.37 (s, 1H, N=CH-Ar), 7.91 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6),
7.32 (t, 1H, J5(4,6) = 8.5 Hz, H-5), 7.36 (s, 1H, H-2), 7.62 (d, 1H, J6,5 = 8.0 Hz, H-6), 7.07 (d, 2H,
J3,5/2,6 = 8.5 Hz, H-3, H-5), 6.83 (d, 1H, J4,5 = 6.5 Hz, H-4), 3.88 (s, 3H, OCH3); Anal. Calcd for

Molecules 2014, 19
1294
C15H14N2O3: C = 66.66, H = 5.22, N= 10.36, O = 17.76, Found C = 66.63, H = 5.19, N = 10.32,
O = 17.74; EI MS m/z (% rel. abund.): 270 (M+, 87), 268 (15), 135 (100), 93 (25).
N'-(4-Hydroxy-3-methoxybenzylidene)-4-methoxybenzohydrazide (11). Solid, M.p.: 181.0 °C; 1H-NMR
(DMSO-d6):  11.57 (s, 1H, NH), 9.56 (s, 1H, OH), 8.33 (s, 1H, N=CH-Ar), 7.91 (d, 2H, J2,6/3,5 =8.5 Hz,
H-2, H-6), 7.33 (s, 1H, H-2), 7.09 (d, 1H, J6,5 = 8.0 Hz, H-6), 7.06 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5),
6.83 (d, 1H, J5,6 = 8.0 Hz, H-5), 3.83 (s, 3H, OCH3), 3.68 (s, 3H, OCH3); Anal. Calcd for C16H16N2O4:
C = 63.99, H = 5.37, N = 9.33, O = 21.31, Found C = 63.94, H = 5.35, N = 9.31, O = 21.29;
EI MS m/z (% rel. abund.): 300 (M+, 90), 135 (100), 122 (25).
1
N'-(3-Hydroxy-4-methoxybenzylidene)-4-methoxybenzohydrazide (12). Solid, M.p.: 213 °C; H-NMR
(DMSO-d6):  11.56 (s, 1H, NH), 9.33 (s, 1H, OH), 8.29 (s, 1H, N=CH-Ar), 7.90 (d, 2H, J2,6/3,5 =9.0 Hz,
H-2, H-6), 7.27 (s, 1H, H-2), 7.09 (d, 1H, J6,5 = 8.5 Hz, H-6), 7.06 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5),
6.98 (d, 1H, J5,6 = 8.5 Hz, H-5), 3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3); Anal. Calcd for C16H16N2O4:
C = 63.99, H = 5.37, N = 9.33, O = 21.31, Found C = 63.94, H = 5.35, N = 9.31, O = 21.29;
EI MS m/z (% rel. abund.): 300 (M+, 70), 135 (100), 122 (30).
1
N'-(2-Hydroxy-5-methoxybenzylidene)-4-methoxybenzohydrazide (13). Solid, M.p.: 202 °C; H-NMR
(DMSO-d6): 11.99 (s, 1H, NH), 10.77 (s, 1H, OH),  8.60 (s, 1H, N=CH-Ar), 7.94 (d, 2H, J2,6/3,5 =8.5 Hz,
H-2, H-6), 7.12 (d, 1H, J3,4 = 8.5 Hz, H-3), 7.09 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 6.95 (dd, 1H,
J4,3 = 8.5, J4,6 = 2.0 Hz, H-4), 6.88 (d, 1H, J6,4 = 2.0 Hz, H-6), 3.84 (s, 3H, OCH3), 3.74 (s, 3H, OCH3);
Anal. Calcd for C16H16N2O4: C = 63.99, H = 5.37, N = 9.33, O = 21.31, Found C = 63.97, H = 5.34,
N = 9.30, O = 21.28; EI MS m/z (% rel. abund.): 300 (M+, 90), 135 (100), 122 (21).
1
4-Methoxy-N-((pyridine-2-methylene)benzohydrazide (14). Solid, M.p.: 107 °C; H-NMR (DMSO-d6):
 11.96 (s, 1H, NH), 8.62 (d, 1H, J6,5 = 5.0Hz, H-6), 8.46 (s, 1H, N=CH-Ar), 7.99 (d, 1H, J3,4 = 8.0 Hz,
H-3), 7.94 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.90 (m, 1H, H-4), 7.60 (t, 1H, J5(4,6) = 8.0 Hz, H-6),
7.09 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 3.87 (s, 3H, OCH3); Anal. Calcd for C14H13N3O2: C = 65.87,
H = 5.13, N= 16.46, O = 12.54, Found C = 65.84, H = 5.09, N = 16.44, O = 12.52; EI MS m/z
(% rel. abund.): 255 (M+, 88), 135 (100), 78 (21).
1
4-Methoxy-N'-(pyridin-4-methylene)benzohydrazide (15). Solid, M.p.: 180 °C; H-NMR (DMSO-d6):
 12.04 (s, 1H, NH), 8.65 (d, 2H, J2,6/3,5 = 6.0 Hz, H-2, H-6), 8.42 (s, 1H, N=CH-Ar), 7.93 (d, 2H,
J2,6/3,5 =8.5 Hz, H-2, H-6), 7.67 (d, 2H, J3,5/2,6 = 6.0 Hz, H-3, H-5), 7.09 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5),
3.84 (s, 3H, OCH3); Anal. Calcd for C14H13N3O2: C = 65.87, H = 5.13, N= 16.46, O = 12.54,
Found C = 65.83, H = 5.11, N = 16.43, O = 12.52; EI MS m/z (% rel. abund.): 255 (M+, 80), 135 (100),
78 (27).
1
4-Methoxy-N'-(pyridin-3-methylene)benzohydrazide (16). Solid, M.p.: 222 °C; H-NMR (DMSO-d6):
 11.92 (s, 1H, NH), 11.92 (s, 1H, H-6), 8.61 (d, 1H, J2,4 = 2.0 Hz, H-2), 8.36 (s, 1H, N=CH-Ar),
8.16 (d, 1H, J4,5 = 8.0 Hz, H-4), 7.93 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.51 (dd, 1H, J5,4 = 8.0
J5,6 = 5.0 Hz, H-5), 7.08 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 3.88 (s, 3H, OCH3); Anal. Calcd for

Molecules 2014, 19
1295
C14H13N3O2: C = 65.87, H = 5.13, N= 16.46, O = 12.54, Found C = 65.82, H = 5.10, N = 16.42,
O = 12.52; EI MS m/z (% rel. abund.): 255 (M+,92), 135 (100), 78 (33).
1
N'-((Furan-2-yl)methylene)-4-methoxybenzohydrazide (17). Solid, M.p.: 207 °C; H-NMR (DMSO-d6):
 11.69 (s, 1H, NH), 8.32 (s, 1H, N=CH-Ar), 7.89 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.84 (s, 1H, H-3),
7.07 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.91 (s, 1H, H-3), 6.64 (dd, 1H, J3,4 = 5.0 Hz, J3,5 = 2.0 Hz, H-3),
3.83 (s, 3H, OCH3); Anal. Calcd for C13H12N2O3: C = 63.93, H = 4.95, N= 11.47, O = 19.65, Found
C = 63.94, H = 4.97, N = 11.46, O = 19.64; EI MS m/z (% rel. abund.): 244 (M+, 94), 135 (100), 68 (23).
Methyl 2-(4-methoxybenzoylimino)methyl)-3,5-dimethoxybenzoate (18). Solid, M.p.: 162 °C;
1H-NMR (DMSO-d6):  11.64 (s, 1H, NH), 8.64 (s, 1H, N=CH-Ar), 7.92 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2,
H-6), 7.06 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 6.76 (d, 1H, J4,6 = 2.0 Hz, H-4), 6.61 (d, 1H,
J6,4 = 2.0 Hz, H-6), 3.89 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, OCH3); Anal. Calcd for
C19H20N2O6: C = 61.28, H = 5.41, N= 7.52, O = 25.78, Found C = 61.26, H = 5.43, N = 7.51,
O = 25.79; EI MS m/z (% rel. abund.): 372 (M+, 25), 195 (40), 135 (100).
N'-(3,4-Dimethoxybenzylidene)-4-methoxybenzohydrazide (19). Solid, M.p.: 179 °C; 1H-NMR
(DMSO-d6):  11.63 (s, 1H, NH), 8.37 (s, 1H, N=CH-Ar), 7.91 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6),
7.36 (s, 1H, H-2), (d, 1H, J6,5 = 8.5 Hz, H-6), 7.07 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 6.76 (d, 1H,
J5,6 = 8.5 Hz, H-4), 3.84 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.81 (s, 3H, OCH3); Anal. Calcd for
C17H18N2O4: C = 64.96, H = 5.77, N= 8.91, O = 20.36, Found C = 64.94, H = 5.74, N = 8.88,
O = 20.35; EI MS m/z (% rel. abund.): 314 (M+, 90), 137 (40), 135 (100).
1
N'-Benzylidene-4-methoxybenzohydrazide (20). Solid, M.p.: 202 °C; H-NMR (DMSO-d6):  11.74
(s, 1H, NH), 8.44 (s, 1H, N=CH-Ar), 7.92 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), (d, 2H, J3,5/2,6 = 6.5 Hz,
H-5 H-6), 7.48–7.44 (m, 3H, H-3, H-4 ,H-5), 7.08 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 3.84 (s, 3H, OCH3);
Anal. Calcd for C15H14N2O2: C = 70.85, H = 5.54, N= 11.02, O = 12.58, Found C = 70.86, H = 5.55,
N = 11.01, O = 12.57; EI MS m/z (% rel. abund.): 254 (M+, 70), 135 (100), 77 (30).
Methyl 4-((4-methoxybenzoylimino)methyl)benzoate (21). Solid, M.p.: 206 °C; 1H-NMR (DMSO-d6): 
11.92 (s, 1H, NH), 8.50 (s, 1H, N=CH-Ar), 8.04 (d, 2H, J2,6/3,5 = 8.0 Hz, H-2/H-6), 7.94 (d, 2H,
J2,6/3,5 =8.5 Hz, H-2, H-6), 7.87 (d, 2H, J3,5/2,6 = 8.0 Hz, H-3/H-5), 7.09 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5),
3.88 (s, 3H, OCH3), 3.84 (s, 3H, OCH3); Anal. Calcd for C17H16N2O4: C = 65.38, H = 5.16, N= 8.97,
O = 20.49, Found C = 65.36, H = 5.15, N = 8.94, O = 20.47; EI MS m/z (% rel. abund.): 312 (M+, 44),
135 (100), 76 (30).
1
N'-(4-Fluorobenzylidene)-4-methoxybenzohydrazide (22). Solid, M.p.: 186 °C; H-NMR (DMSO-d6):
 11.76 (s, 1H, NH), 8.44 (s, 1H, N=CH-Ar), 7.92 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.80 (t, 2H,
J2,6/2,6,F = 7.0 Hz, H-2/H-6), 7.32 (t, 2H, J3,5/2,6,F = 7.0 Hz, H-2/H-6), 7.07 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5),
3.84 (s, 3H, OCH3); Anal. Calcd for C15H13FN2O2: C = 66.17, H = 4.81, F = 6.98, N = 10.29,
O = 11.75, Found C = 66.13, H = 4.79, F = 6.95, N = 10.27, O = 11.73; EI MS m/z (% rel. abund.):
272 (M+, 78), 135 (100), 95 (30).

Molecules 2014, 19
1296
1
N'-(3-Methoxybenzylidene)-4-methoxybenzohydrazide (23). Solid, M.p.: 121.6 °C; H-NMR (DMSO-d6):
 11.74 (s, 1H, NH), 8.41 (s, 1H, N=CH-Ar), 7.92 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.40 (t, 1H,
J5(4,6) = 7.5 Hz, H-5), 7.30–725 (m, 1H, H-4), 7.07 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 7.81 (dd, 1H,
J
6,5 = 7.5 Hz, J6,4 = 2.0 Hz, H-6), 3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3); Anal. Calcd for C16H16N2O3:
C = 67.59, H = 5.67, N= 9.85, O = 16.88, Found C = 67.57, H = 5.64, N = 9.82, O = 16.85; EI MS m/z
(% rel. abund.): 284 (M+, 55), 135 (100), 107 (30).
1
N'-(4-Methoxybenzylidene)-4-methoxybenzohydrazide (24). Solid, M.p.: 174 °C; H-NMR (DMSO-d6):
 11.62 (s, 1H, NH), 8.37 (s, 1H, N=CH-Ar), 7.91(d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.68 (d, 2H,
J2,6/3,5 =8.0 Hz, H-2, H-6), 7.07 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 7.03(d, 2H, J3,5/2,6 = 8.0 Hz, H-3, H-5),
3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3); Anal. Calcd for C16H16N2O3: C = 67.59, H = 5.67, N= 9.85,
O = 16.88, Found C = 67.57, H = 5.64, N = 9.82, O = 16.85; EI MS m/z (% rel. abund.): 284 (M+, 85),
135 (100), 95 (40).
1
N'-(4-Chlorobenzylidene)-4-methoxybenzohydrazide (25). Solid, M.p.: 198 °C; H-NMR (DMSO-d6):
 11.80 (s, 1H, NH), 8.37 (s, 1H, N=CH-Ar), 7.912 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.76 (d, 2H,
J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.54 (d, 2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 7.07 (d, 2H, J3,5/ 2,6 = 9.0 Hz, H-3,
H-5), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3); Anal. Calcd for C15H13ClN2O2: C = 62.40, H = 4.54,
N= 9.70, O = 11.08, Found C = 62.41, H = 4.53, N = 9.71, O = 11.06; EI MS m/z (% rel. abund.):
290 (M++2, 100), 288 (M+, 32), 135 (100), 113 (15), 111 (50).
1
4-Methoxy-N'-(thiophen-2-methylene)benzohydrazide (26). Solid, M.p.: 209 °C; H-NMR (DMSO-d6):
 11.67 (s, 1H, NH), 8.65 (s, 1H, N=CH-Ar), 7.90 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6), 7.65 (d, 1H,
J3,4 = 5.0 Hz, H-3), 7.45 (d, 1H, J5,4 = 3.0 Hz, H-5), 7.15 (d, 1H, J4,5 = 5.0, J4,3 = 3.0 Hz, H-4),
7.06 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 3.84 (s, 3H, OCH3); Anal. Calcd for C13H12N2O2S: C = 59.98,
H = 4.65, N= 10.76, O = 12.29, S = 12.32, Found C = 59.96, H = 4.63, N = 10.74, O = 12.27,
S = 12.30; EI MS m/z (% rel. abund.): 260 (M+, 65), 135 (100), 83 (28).
1
N'-(3-Bromo-4-hydroxybenzylidiene)-2-methoxybenzohydrazide (27). Solid, M.p.: 209 °C; H-NMR
(DMSO-d6):  11.67 (s, 1H, NH), 10.83 (s, 1H, OH), 8.30 (s, 1H, N=CH-Ar), 7.91 (d, 2H,
J2,6/3,5 =8.5 Hz, H-2, H-6), 7.86 (s, 1H, H-2), 7.56 (d, 1H, J6,5 = 8.0 Hz, H-6), 7.06 (d, 2H, J3,5/2,6 = 9.0 Hz,
H-3, H-5), 7.03 (d, 1H, J5,6 = 8.0 Hz, H-5), 3.84 (s, 3H, OCH3); Anal. Calcd for C15H13BrN2O3: C = 51.60,
H = 3.75, Br = 22.88, N= 8.02, O = 13.75, Found C = 51.57, H = 3.73, Br = 22.85, N = 7.99, O = 13.73;
EI MS m/z (% rel. abund.): 350 (M+2, 56), 348 (M+, 57), 172 (26), 170 (25), 135 (100), 92 (20).
N'-(3-Hydroxy-2-iodo-4-methoxybenzylidene)-4-methoxybenzohydrazide(28). Solid, M.p. = 147 °C;
1H-NMR (DMSO-d6):  11.65 (s, 1H, NH), 9.72 (s, 1H, OH), 8.68 (s, 1H, N=CH-Ar), 7.93 (d, 2H,
J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.50 (d, 1H, J6,5 = 8.0 Hz, H-6), 7.09 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.06 (d,
2H, J3,5/2,6 = 8.5 Hz, H-3, H-5), 3.87 (s, 3H, OCH3); Anal. Calcd for C16H15IN2O4: C = 45.09, H = 3.55,
I = 29.78, N= 6.57, O = 15.02, Found C = 45.07, H = 3.53, I = 29.77, N = 6.55, O = 14.99; EI MS m/z
(% rel. abund.): 426 (M+, 15), 299 (36), 248 (20), 135 (100).

Molecules 2014, 19
1297
1
N'-(3,5-Dimethoxybenzylidene)-2-methoxybenzohydrazide (29). Solid, M.p. = 184 °C; H-NMR
(DMSO-d6):  11.78 (s, 1H, NH), 8.36 (s, 1H, N=CH-Ar), 9.92 (d, 2H, J2,6/3,5 = 9.0 Hz, H-2, H-6),
7.08 (d, 2H, J3,5/2,6 = 9.0 Hz, H-3, H-5), 6.89 (s, 2H, H-2, H-6), 6.57 (s, 1H, H-4), 3.84 (s, 3H,OCH3),
3.79 (s, 6H, OCH3); Anal. Calcd for C17H18N2O4: C = 64.96, H = 5.77, N = 8.91, O = 20.36, Found
C = 64.95, H = 5.77, N = 8.88, O = 20.33; EI MS m/z (% rel. abund.): 314 (M+, 81), 137 (36), 135 (100).
1
N'-(4-Nitrobenzylidiene)-4-methoxybenzohydrazide (30). Solid, M.p. = 240 °C; H-NMR (DMSO-d6):
 12.08 (s, 1H, NH), 8.53 (s, 1H, N=CH-Ar), 8.31 (d, 2H, J2,6/3,5 = 8.0 Hz, H-2, H-6), 8.00 (d, 2H,
J3,5/2,6 = 8.0 Hz, H-3, H-5), 7.94 (d, 2H, J2,6/3,5 = 8.5 Hz, H-2, H-6), 7.09 (d, 2H, J3,5/ 2,6 = 8.5 Hz, H-3,
H-5), 3.85 (s, 3H, OCH3); Anal. Calcd for C15H13N3O4: C = 60.20, H = 4.38, N= 14.04, O = 21.38,
Found C = 60.17, H = 4.35, N = 14.02, O = 21.37; EI MS m/z (% rel. abund.): 301 (M+, 94), 135 (100).
122 (35), 76 (20).
3.2.3. Protocol for Antiglycation Activity
Bovine Serum Albumin (BSA) was purchased from Merck Marker Pvt. Ltd. (Darmstadt, Germany),
rutin and methylglyoxal (MG) (40% aqueous solution) were from Sigma Aldrich (Tokyo, Japan),
sodium dihydrogen phosphate (NaH2PO4), disodium hydrogen phosphate (Na2HPO4) and sodium azide
(NaN3) were purchased from Scharlau Chemie, S. A. (Barcelona, Spain), while dimethyl sulphoxide
(DMSO) was purchased from Fischer Scientific (Loughborough, UK). Bovine Serum Albumin (10
mg/mL), methyl glyoxal (14 mM), various concentrations of the compounds (prepared in DMSO, 10%
final concentration), and 0.1 M phosphate buffer (pH 7.4) containing sodium azide (30 mM) was
incubated under aseptic conditions at 37 °C for 9 days. After 9 days, each sample was examined for the
development of specific fluorescence (excitation, 330 nm; emission, 440 nm) against sample blank [39,57].
Rutin was used as a positive control. All of the experiments were done in a 96-well microplate reader
(SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). The percent inhibition of AGE formation in
the test sample versus control was calculated for each inhibitor compound by using the following formula:
% inhibition= (1 − fluorescence of test sample/Fluorescence of the control group) × 100
(1)
3.3. Software/Statistical
The obtained results were analysed by SoftMaxPro 4.8 and MS-Excel. Results are presented as
means ± SEM from three experiments. IC50 Values were determined by using EZ-FIT, Enzyme
kinetics software by Perrella Scientific, Inc., Hillsborough, NH, USA.
4. Conclusions
In conclusion, compounds having hydroxy groups showed good antiglycation activity due to their
capacity to inhibit glycoxidation. However, structural modifications can be optimized to achieve the
desired activity in this class of compounds.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/1/1302/s1.

Molecules 2014, 19
1298
Acknowledgments
The authors would like to acknowledge Universiti Teknologi MARA for the financial support under
the Research Intensive Faculty grant scheme with reference number UiTM 600-RMI/DANA 5/3/RIF
(347/2012).
Conflict of Interest
The authors declare no conflict of interest.
References
1. Cimerman, Z.; Miljanić, S.; Galic, N. Schiff Bases derived from aminopyridines as
spectrofluorimetric analytical reagents. Croat. Chem. Acta 2000, 73, 81–95.
2. Musharraf, S.G.; Bibi, A.; Shahid, N.; Najam-ul-Haq, M.; Khan, M.; Taha, M.; Mughal, U.R.;
Khan, K. Acylhydrazide and isatin Schiff bases as alternate UV-laser desorption ionization (LDI)
matrices for low molecular weight (LMW) peptides analysis. Am. J. Anal. Chem. 2012, 3, 779–789.
3. Tarafder, M.T.; Kasbollah, A.; Saravan, N.; Crouse, K.A.; Ali, A.M.; Tin, O.K.
S-methyldithiocarbazate and its Schiff bases: Evaluation of bondings and biological properties.
J. Biochem. Mol. Biol. Biophys. 2002, 6, 85–91.
4. Kabak, M.; Elmali, A.; Elerman, Y. Keto–enol tautomerism, conformations and structure of
N-(2-hydroxy-5-methylphenyl), 2-hydroxybenzaldehyde-imine. J. Mol. Struct. 1999, 477, 151–158.
5. Küçükgüzel, I.; Küçükgüzel, Ş.G.; Rollas, S.; Otuk-Saniş, G.; Özdemir, O.; Bayrak, İ.; Altuğ, T.;
Stables, J.P. Synthesis of some 3-(arylalkylthio)-4-alkyl/aryl-5-(4-aminophenyl)-4H-1,2,4-triazole
derivatives and their anticonvulsant activity. Il Farmaco 2004, 59, 839–891.
6. Taha, M.; Ismail, N.H.; Jamil, W.; Yousuf, S.; Jaafar, F.M.; Ali, M.I.; Kashif, S.M.;
Hussain, E. Synthesis, evaluation of antioxidant activity and crystal structure of
2,4-dimethylbenzoylhydrazones. Molecules 2013, 18, 10912–10929.
7. Pandeya, S.N.; Sriram, D.; Nath, G.; de Clercq, E. Synthesis, antibacterial, antifungal and
anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-
methylmercapto quinazolin-4(3H)-one. Pharm. Acta Helv. 1999, 74, 11–17.
8. Pandeya, S.N.; Sriram, D.; Nath, G.; DeClercq, E. Synthesis, antibacterial, antifungal and
anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and
N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide. Eur. J. Pharm. Sci. 1999, 9, 25–31.
9. Loncle, C.; Brunel, J.M.; Vidal, N.; Dherbomez, M.; Letourneux, Y. Synthesis and antifungal
activity of cholesterol-hydrazone derivatives. Eur. J. Med. Chem. 2004, 39, 1067–1071.
10. Küçükgüzel, S.G.; Mazi, A.; Sahin, F.; Öztürk, S.; Stables, J. Synthesis and biological activities of
diflunisal hydrazide-hydrazones. Eur. J. Med. Chem. 2003, 38, 1005–1013.
11. Todeschini, A.R.; de Miranda, A.L.; Silva, C.M.; Parrini, S.C.; Barreiro, E.J. Synthesis and
evaluation of analgesic, anti-inflammatory and antiplatelet properties of new
2-pyridylarylhydrazone derivatives. Eur. J. Med. Chem. 1998, 33, 189–199.
12. Melnyk, P.; Leroux, V.; Sergheraert, C.; Grellier, P. Design, synthesis and in vitro antimalarial
activity of an acylhydrazone library. Bioorg. Med. Chem. Lett. 2006, 16, 31–35.
13. Leite, L.F.C.C.; Ramos, M.N.; Da Silva, J.B.P.; Miranda, A.L.P.; Fraga, C.A.M.; Barreiro, E.J.

Molecules 2014, 19
1299
Synthesis and analgesic profile of novel N-containing heterocycle derivatives: Arylidene 3-
phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco 1999, 54, 747–757.
14. Lima, P.C.; Lima, L.M.; Da Silva, K.C.; Léda, P.H.; de Miranda, A.L.; Fraga, C.A.; Barreiro, E.J.
Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural
safrole. Eur. J. Med. Chem. 2000, 35, 187–203.
15. Cunha, A.C.; Figueiredo, J.M.; Tributino, J.L.M.; Miranda, A.L.P.; Castro, H.C.; Zingali, R.B.;
Fraga, C.A.M.; de Souza, M.C.B.V.; Ferreira, V.F.; Barreiro, E.J. Antiplatelet properties of novel
N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorg. Med. Chem. 2003, 11,
2051–2059.
16. Kaymakçıoğlu, K.B.; Oruç, E.E.; Unsalan, S.; Kandemirli, F.; Shvets, N.; Rollas, S.; Anatholy, D.
Synthesis and characterization of novel hydrazide-hydrazones and the study of their structure
antituberculosis activity. Eur. J. Med. Chem. 2006, 41, 1253–1261.
17. Terzioglu, N.; Gürsoy, A. Synthesis and anticancer evaluation of some new hydrazone derivatives
of 2,6-dimethylimidazo[2,1-b]-[1,3,4]thiadiazole-5-carbohydrazide. Eur. J. Med. Chem. 2003, 38,
781–786.
18. Sawada, Y.; Yanai, T.; Nakagawa, H.; Tsukamoto, Y.; Tamagawa, Y.; Yokoi, S.; Yanagi, M.;
Toya, T.; Sugizaki, H.; Kato, Y.; et.al. Synthesis and insecticidal activity of benzoheterocyclic
analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide: Part 1. Design of benzoheterocyclic
analogues. Pest Manag. Sci. 2003, 59, 25–35.
19. Taha, M.; Baharudin, M.S.; Ismail, N.H.; Khan, K.M.; Jaafar, F.M.; Samreen; Siddiqui, S.;
Choudhary, M.I. Synthesis of 2-methoxybenzoylhydrazone and evaluation of their antileishmanial
activity. Bioorg. Med. Chem. Lett. 2013, 23, 3463–3466.
20. Küçükgüzel, S.G.; Rollas, S. Synthesis, characterization of novel coupling products and
4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. Il Farmaco 2002, 57,
583–587.
21. Greenfield, R.S.; Kaneko, T.; Daues, A.; Edson, M.A.; Fitzgerald, K.A.; Olech, L.J.; Grattan, J.A.;
Spitalny, G.L.; Braslawsky, G.R. Evaluation in vitro of adriamycin immunoconjugates
synthesized using an acid-sensitive hydrazone linker. Cancer Res. 1990, 50, 6600–6007.
22. Caffery, C.R.; Schanz, M.; Nkemgu-Njinkeng, J.; Brush, M.; Hansell, E.; Cohen, F.E.;
Flaherty, T.M.; Mckerrow, J.H. Steverding, D. Screening of acyl hydrazide proteinase inhibitors
for antiparasitic activity against Trypanosoma brucei. Int. J. Anitimicrob. Agents 2002, 19, 227–231.
23. Khan, K.M.; Shujaat, S.; Rahat, S.; Hayat, S.; Atta-ur-Rahman; Choudhary, M.I. β-N-Cyanoethyl
acyl hydrazide derivatives: A new class of β-glucuronidase inhibitors. Chem. Pharm. Bull. Jpn.
2002, 50, 1443–1446.
24. Mansour, A.K.; Eid, M.M.; Khalil, N.S.A.M. Synthesis and reactions of some new heterocyclic
carbohydrazides and related compounds as potential anticancer agents. Molecules 2003, 8, 744–755.
25. Patole, J.; Sandbhor, U.; Padhye, S.; Deobagkar, D.N.; Anson, C.E.; Powell, A.
Structural chemistry and in vitro antitubercular activity of acetylpyridine benzoyl hydrazone and
its copper complex against Mycobacterium smegmatis. Bioorg. Med. Chem. Lett. 2003, 13, 51–55.
26. Ragnarsson, U. Synthetic methodology for alkyl substituted hydrazines. Chem. Soc. Rev. 2001,
30, 205–213.
27. Reddy, V.P.; Beyaz, A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for
multiple diseases. Drug Discov. Today 2006, 11, 646–654.

Molecules 2014, 19
1300
28. Ahmed, N. Advanced glycation end products-role in pathology of diabetic complications.
Diabetes Res. Clin. Pract. 2005, 67, 3–21.
29. Brownlee, M. Glycation and complications Diabetes. Diabetes 1994, 43, 836–841.
30. Peppa, M.; Uribarri, J.; Vlassara, H. Glucose, advanced glycation end products, and diabetes
complications: What is new and what works. Clin. Diabetes 2003, 21, 186–187.
31. Monnier, V.M. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 2003,
419, 1–15.
32. Vasan, S.; Foiles, P.; Founds, H. Therapeutic potential of breakers of advanced glycation end
product–protein crosslinks. Arch. Biochem. Biophys. 2003, 419, 89–96.
33. Hunt, J.V.; Bottoms, M.A.; Mitchinson, M.J. Oxidative alterations in the experimental glycation
model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental
differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem. J.
1993, 291, 529–535.
34. Ahmed, M.S.; Ahmed, N. Antiglycation properties of aged garlic extract: Possible role in
prevention of diabetic complications. Am. Soc. Nutr. 2006, 136, 796S–799S.
35. Gugliucci, A. Glycation as the glucose link to diabetic complications J. Am. Osteopath. Assoc.
2000, 100, 621–634.
36. Gugliucci, A.; Menini, T. The polyamines spermine and spermidine protect proteins from
structural and functional damage by AGE precursors: A new role for old molecules. Life Sci.
2003, 72, 2603–2616.
37. Choudhary, M.I.; Adhikari, A.; Rasheed, S.; Marasini, B.P.; Hussain, N.; Kaleem, W.A.;
Atta-ur-Rahman. Cyclopeptide alkaloids of Ziziphus oxyphylla Edgw as novel inhibitors of
α-glucosidase enzyme and protein glycation. Phytochem. Lett. 2011, 4, 404–406.
38. Choudhary, M.I.; Ali, M., Wahab, A.; Khan, A.; Rasheed, S.; Shyaula, S.L.; Rahman, A.U.
New antiglycation and enzyme inhibitors from Parmotrema cooperi. Sci. China Chem. 2011, 54,
1926–1931.
39. Atta-ur-Rahman; Choudhary, M.I.; Basha, F.Z.; Abbas, G.; Khan, S.N.; Shah, S.A.A.
Science at the interface of chemistry and biology: Discoveries of α-glucosidase inhibitors and
antiglycation agents. Pure Appl. Chem. 2007, 79, 2263–2268.
40. Ayatollahi, S.A.M.; Kobarfard, F.; Asgarpanah, J.; Choudhary, M.I. Antiglycation activity of
Otostegia persica (Burm) Boiss. Afr. J. Biotechnol. 2010, 9, 3645–3648.
41. Khan, K.M.; Taha, M.; Rahim, F.; Fakhri, M.I.; Jamil, W.; Khan, M.; Rasheed, S.; Karim, A.;
Perveen, S.; Choudhary, M.I. Acylhydrazide schiff bases: Synthesis and antiglycation activity.
J. Pak. Chem. Soc.2013, 35, 929–937.
42. Khan, K.M.; Rahim, F.; Ambreen, N.; Taha, M.; Khan, M.; Jahan, H.; Najeebullah, U.;
Shaikh, A.; Iqbal, S.; Perveen, S; et.al. Synthesis of benzophenonehydrazone Schiff bases and
their in vitro antiglycating activities. Med. Chem. 2013, 9, 588–595.
43. Khan, K.M.; Shah, Z.; Ahmad, V.U.; Khan, M.; Taha, M.; Rahim, F.; Jahun, H.; Perveen, S.;
Choudhary, M.I. Synthesis of 2,4,6-trichlorophenyl hydrazones and their inhibitory potential
against glycation of protein. Med. Chem. 2011, 7, 572–580.
44. Khan, K.M.; Khan, M.; Ambreen, N.; Taha, M.; Rahim, F.; Rasheed, S.; Saied, S.; Shafi, H.;
Perveen, S.; Choudhary, M.I. Oxindole derivatives: Synthesis and antiglycation activity.
Med. Chem. 2013, 9, 681–688.

Molecules 2014, 19
1301
45. Khan, K.M.; Khan, M.; Ali, M.; Taha, M.; Rasheed, S.; Perveen, S.; Choudhary, M.I. Synthesis of
bis-Schiff bases of isatins and their antiglycation activity. Bioorg. Med. Chem. 2009, 17, 7795–7801.
46. Zeb, A.; Malik, I.; Rasheed, S.; Choudhary, M.I.; Basha, F.Z. Metronidazole esters: A new class
of antiglycation agents. Med. Chem. 2012, 8, 846–852.
47. Taha, M.; Ismail, N.H.; Jaafar, F.M.; Aziz, A.N.; Yousuf, S. (E)-N'-(3,4Dihydroxybenzylidene)-
2,4-dimethylbenzohydrazide monohydrate. Acta Cryst. 2013, E69, o490.
48. Baharudin, M.S.; Taha, M.; Ismail, N.H.; Shah, S.A.A., Yousuf, S. (E)-N'-(4-Chlorobenzylidene)-
2-methoxybenzohydrazide. Acta Cryst. 2013, E69, o276.
49. Taha, M.; Baharudin, M.S.; Ismail, N.H.; Shah, S.A.A.; Yousuf, S. (E)-2-Methoxy-N'-(2,4,6-
trihydroxybenzylidene)Benzohydrazide. Acta Cryst. 2013, E69, o277.
50. Taha, M.; Ismail, N.H.; Jaafar, F.M.; Khan, K.M.; Yousuf, S. (E)-2,4-Dimethyl-N'-(2-
methylbenzylidene) benzohydrazide. Acta Cryst. 2013, E69, o400.
51. Baharudin, M.S.; Taha, M.; Ismail, N.H.; Shah, S.A.A.; Yousuf, S. N-[(E)-2-Hydroxy-5-
methoxybenzylidene]-2-methoxybenzohydra-zide. Acta Cryst. 2012, E68, o3255.
52. Taha, M.; Baharudin, M.S.; Ismail, N.H.; Shah, S.A.A.; Yousuf, S. N'-[(E)-2,3-
Dihydroxybenzylidene]-2-methoxybenzohydrazide. Acta Cryst. 2012, E68, o3256.
53. Taha, M.; Naz, H.; Rahman, A.A.; Ismail, N.H.; Yousuf, S. (E)-4-Methoxy-N'-[(pyridin-4-
yl)methylidene] benzohydrazide monohydrate. Acta Cryst. 2012, E68, o2778.
54. Taha, M.; Naz, H.; Rahman, A.A.; Ismail, N.H.; Yousuf, S. (E)-N-(3,4-Dimethoxybenzylidene)-4-
methoxybenzohydrazide. Acta Cryst. 2012, E68, o2780.
55. Naz, H.; Taha, M.; Rahman, A.A.; Ismail, N.H.; Yousuf, S Methyl (E)-3,5-dimethoxy-2-{[2-(4-
methoxybenzoyl)hydrazin-1-ylidene]- methyl}benzoate. Acta Cryst. 2012, E68, o2671.
56. Taha, M.; Naz, H.; Rahman, A.A.; Ismail, N.H.; Yousuf, S (E)-4-Methoxy-N'-(3,4,5-
trihydroxybenzylidene)benzohydrazide methanol monosolvate. Acta Cryst. 2012, E68, o2846.
57. Cho, S.J.; Roman, G.; Yeboah, F.; Konishi, Y. The road to advanced glycation end products:
A mechanistic perspective. Curr. Med. Chem. 2007, 14, 1653–1671.
Sample Availability: Not available.
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).